NeurogesX Completes Enrollment In Confirmatory Phase 3 Clinical Trial For Painful HIV Distal Sensory Polyneuropathy
NeurogesX, Inc. (Nasdaq: NGSX) announced that it has completed enrollment in study C119, a second Phase 3 clinical trial of its lead product candidate NGX-4010 for the treatment of painful HIV-distal sensory polyneuropathy (HIV-DSP). NGX-4010 is a dermal patch designed to manage peripheral neuropathic pain. [click link for full article]
More: continued here
Filed under: HIV / AIDS on September 25th, 2007